Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
about
Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory diseaseA recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.Inhibition of human parainfluenza virus type 3 infection by novel small moleculesEpidemiology of acute respiratory infections in children in Guangzhou: a three-year study.Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice.Vaccines: past, present and future.Epidemiology and clinical presentation of the four human parainfluenza virus types.Immunization strategies for the prevention of pneumovirus infections.Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate ModelMutations in the DI-DII Linker of Human Parainfluenza Virus Type 3 Fusion Protein Result in Diminished Fusion Activity.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.Carriers for the delivery of a vaccine against respiratory syncytial virus.Need for a safe vaccine against respiratory syncytial virus infection.Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageSendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsHuman PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.Mucosal vaccines: novel advances in technology and delivery.Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.Respiratory syncytial virus: immunopathology and control.Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.Advances in and the potential of vaccines for respiratory syncytial virus.Recent advances in the development of subunit-based RSV vaccines.Viral etiology, seasonality and severity of hospitalized patients with severe acute respiratory infections in the Eastern Mediterranean Region, 2007-2014.Coptidis Rhizoma extract inhibits replication of respiratory syncytial virus in vitro and in vivo by inducing antiviral state.Virucide properties of cold atmospheric plasma for future clinical applications.Multivalent and Multipathogen Viral Vector Vaccines.Molecular characterization of human parainfluenza virus type 1 in infants attending Mbagathi District Hospital, Nairobi, Kenya: a retrospective study.Characterizing the Cellular Immune Response to Parainfluenza Virus 3.The use of multiplex PCR for the diagnosis of viral severe acute respiratory infection in children: a high rate of co-detection during the winter season.Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.Respiratory syncytial virus vaccine development
P2860
Q24530163-25F8C9B3-DAD4-4486-944A-1CC79978368FQ33285591-4C544262-EA73-4320-9869-6CD01C5246ACQ33304137-1F353840-C509-4D55-96C1-68B7156C7707Q33568059-CA8B70B1-D462-4F36-8617-0B5A75A1A991Q34353365-9DA90CC8-7C76-448E-8C10-8FE5B33C7BF7Q34409178-7C45AC63-AE56-44C7-805E-775B1D4DB88DQ34559960-5C73B48C-3315-486A-9E0F-6FFB17BDC5ADQ34615678-4CC5B1B3-3C4F-40A1-A2DF-B0BCE4E687A8Q35641632-81A413E7-EF8A-458A-AAE5-DD09870A720AQ35754943-BD51A149-7888-43A0-B2EB-2CB74204D29FQ36005114-BEC4C756-E9C6-4550-90A5-95E6D823D2B9Q36086315-9BF6EA92-7F02-4DC4-A1ED-5BB03D3C72BCQ36194078-7652C539-BD02-4A20-B305-CF0B80EA6900Q36266896-4943F85A-60C0-46C8-8083-E9377889529CQ36449078-79B6358E-946A-4D95-B6FC-FF09E96A521BQ36530226-96699EE3-FDB7-465F-8144-69FE25A2A125Q36827280-5D9E30CC-A840-4A53-A994-2F5B56DB5764Q37265589-BC315246-8DCF-4131-A7C2-03394EDCAA9DQ37308711-171CA56E-106D-41CD-B5EE-C865EF6CE9F8Q37348134-E68981C4-B1C2-48D7-AF61-856D56FB7705Q37470206-A930CCA7-4ACF-46E7-9AB4-53995DBC4164Q37559647-E0745C2A-385E-4839-9B1E-20A852159557Q37568127-85060205-BBED-4D1A-9B83-D7CD86A68DECQ37754763-8446BCAE-527C-4BB7-903F-D47A2E1962E1Q37841269-28C3D3E7-EBB1-44E5-857A-EF9CFBA75891Q38130514-AE54E1C3-7164-44CF-8E5F-F51326EB884BQ38617302-4C31A6A3-6B61-4549-AFB5-88BF2421A759Q38680876-0DDD28E8-F301-4E5F-9617-6657F059AA42Q38702032-68548CA3-24C6-43E4-873E-715BF1B7A374Q38815371-D1FCD84E-8E9A-497A-B211-40E67970B16EQ38830323-757573B6-21C4-4B4C-87F5-07DA5D7A1909Q39138545-DBB41F20-471B-4DB5-A44F-1F6A7F7DABFEQ40215048-31B12741-9442-40FD-97C6-59722E4CC5C4Q40707215-B5F88845-9B2C-476E-94BF-59E3B74CC20DQ44480572-B7E1F4D8-76B5-4165-B0BC-A1550A11F172Q45392073-43C5D3A6-19C5-4E3A-B83D-155BA4D74E82Q56893551-D8B07EB0-4C49-4D75-82D9-F4CC48FA6754
P2860
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Progress in the development of ...... parainfluenza virus vaccines.
@ast
Progress in the development of ...... parainfluenza virus vaccines.
@en
Progress in the development of ...... parainfluenza virus vaccines.
@nl
type
label
Progress in the development of ...... parainfluenza virus vaccines.
@ast
Progress in the development of ...... parainfluenza virus vaccines.
@en
Progress in the development of ...... parainfluenza virus vaccines.
@nl
prefLabel
Progress in the development of ...... parainfluenza virus vaccines.
@ast
Progress in the development of ...... parainfluenza virus vaccines.
@en
Progress in the development of ...... parainfluenza virus vaccines.
@nl
P356
P1476
Progress in the development of ...... parainfluenza virus vaccines.
@en
P304
P356
10.1086/379775
P407
P577
2003-11-20T00:00:00Z